Zydus Lifesciences Ltd. share price and momentum signal (NSE: ZYDUSLIFE)
NSE · Healthcare · Data to 4 Nov 2026
Current signal
Low Signal
The probability is the model's estimate that the closing price 34 calendar days later will be above its 150-day exponential moving average. High is 52.5% and above, Moderate from 50.5%. How the signal works.
Price and model probability, last 12 months
Last 10 trading days as a table
| Date | Adjusted close | Model probability |
|---|---|---|
| 4 Nov 2026 | ₹1,188.10 | 48.7% |
| 3 Nov 2026 | ₹1,240.60 | 48.8% |
| 2 Nov 2026 | ₹1,240.50 | 48.9% |
| 30 Oct 2026 | ₹1,245.50 | 48.8% |
| 29 Oct 2026 | ₹1,184.40 | 48.4% |
| 28 Oct 2026 | ₹1,175.50 | 48.5% |
| 27 Oct 2026 | ₹1,172.90 | 48.5% |
| 26 Oct 2026 | ₹1,160.40 | 48.7% |
| 23 Oct 2026 | ₹1,129.40 | 49.5% |
| 22 Oct 2026 | ₹1,135.00 | 48.4% |
Key figures
- 1 month
- +4.3%
- 3 months
- +6.0%
- 6 months
- +26.6%
- 12-month high
- ₹1,245.50 30 Oct 2026
- 12-month low
- ₹860.60 23 Mar 2026
- From the high
- -4.6%
Changes are in adjusted closing price to 4 Nov 2026; the 12-month range covers trading since 4 Nov 2025.
Updates on Zydus Lifesciences
-
Signal moved from Moderate to High
On 28 Oct 2026 the model's 5-day average probability for Zydus Lifesciences rose to 83.9%, above the 80% High threshold, after 2 sessions at Moderate. It closed at ₹1,175.50 that day.
Reviewed by Ruchika Patel
-
Signal moved from Low to Moderate
On 26 Oct 2026 the model's 5-day average probability for Zydus Lifesciences rose to 66.5%, above the 60% Moderate threshold, after 6 sessions at Low. It closed at ₹1,160.40 that day.
Reviewed by Ruchika Patel
-
Signal moved from Moderate to Low
On 16 Oct 2026 the model's 5-day average probability for Zydus Lifesciences fell to 58.9%, below the 60% Moderate threshold, after 5 sessions at Moderate. It closed at ₹1,123.00 that day.
Reviewed by Ruchika Patel
-
Signal moved from High to Moderate
On 9 Oct 2026 the model's 5-day average probability for Zydus Lifesciences fell to 74.8%, below the 80% High threshold, after 12 sessions at High. It closed at ₹1,117.50 that day.
Reviewed by Ruchika Patel
Research on Zydus Lifesciences
No research notes on Zydus Lifesciences yet.
Other Healthcare stocks
- Apollo Hospitals Enterprise Low Signal
- Cipla Low Signal
- Divi's Laboratories Low Signal
- Dr. Reddy's Laboratories Low Signal
- Max Healthcare Institute Low Signal
- Sun Pharmaceutical Industries Moderate Signal
- Torrent Pharmaceuticals Moderate Signal
Questions about Zydus Lifesciences
What is the current PredictivePick momentum signal for Zydus Lifesciences?
As of 4 Nov 2026, Zydus Lifesciences Ltd. (ZYDUSLIFE) has a Low Signal. Its model probability, averaged over the last 5 trading days, is 48.7%. The signal is High at 52.5% and above, Moderate from 50.5%, and Low below that.
How has the Zydus Lifesciences share price moved recently?
Based on adjusted closing prices to 4 Nov 2026, Zydus Lifesciences has changed +4.3% over one month, +6.0% over three months and +26.6% over six months. Since 4 Nov 2025 it has traded between ₹860.60 and ₹1,245.50.
Which sector is Zydus Lifesciences in?
Zydus Lifesciences is classified under Healthcare. Other Healthcare stocks PredictivePick covers include Apollo Hospitals Enterprise, Cipla, Divi's Laboratories, Dr. Reddy's Laboratories, Max Healthcare Institute, Sun Pharmaceutical Industries, Torrent Pharmaceuticals.
What does the PredictivePick signal for Zydus Lifesciences measure?
It is the model's estimated probability that the stock's closing price 34 calendar days later will be above its 150-day exponential moving average. It is a statistical estimate, not a price target or a recommendation. Signals are model estimates calculated from publicly available market data. They are not investment advice, do not represent actual trading results, and are not claimed to be accurate or complete.
Signals are model estimates calculated from publicly available market data. They are not investment advice, do not represent actual trading results, and are not claimed to be accurate or complete. See the full disclaimer.